Reid Huber

Reid Huber has a diverse work experience in the biotechnology and pharmaceutical industry. Reid is currently a Partner at Third Rock Ventures, a position they have held since December 2018. In addition, they are also the Director of Rapport Therapeutics, starting in December 2022. Previously, Reid served as the Director and CEO of MOMA Therapeutics from April 2020 to April 2021. Reid has also held director-level positions at Terremoto Biosciences, Tango Therapeutics, Asher Biotherapeutics, and Bellicum Pharmaceuticals, Inc. Reid's involvement in the industry extends beyond individual companies, as they have served as a Board Observer at insitro and as a Director for the Eastern New England Board of the American Cancer Society and the Partners HealthCare Innovation Growth Board.

Reid Huber obtained a Bachelor of Science degree in Molecular Genetics/Biochemistry from Murray State University, where they studied from 1991 to 1994. Reid further pursued their academic career at Washington University School of Medicine in St. Louis, completing their PhD in Molecular Genetics/Biochemistry from 1994 to 1998.